Treatment with PD-1 antibody increased the activation of CD8+ T cells (Fig. 2g,h) and the numbers of CD4+ and CD8+ TEF cells in Shp2f/f, but not in Shp2f/fLysMCre tumor-bearing mice (Fig. 2i,j), which had more TEF cells in dLN in both IgG2a and PD-1 Ab treatment groups (Fig. 2i). Here, CD8A is linked to neoplasm.